TORNTPHARM Q3 FY24 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,732 Cr
verified against source
Revenue YoY
10%
reported change
EBITDA
₹869 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Torrent Pharma delivered a solid Q3 FY24 with revenue of INR 2,732 crore (+10% YoY) and EBITDA of INR 869 crore (+20% YoY), with margin expanding 200bps to 31.8%. India remains the growth engine at INR 1,415 crore (+12%), outperforming the 9% IPM market by 300bps through new launches and field force expansion. Brazil posted 17% CC growth with strong new product momentum, while Germany saw steady 5% growth with incremental tender wins from next fiscal. U.S. sales at $33 million declined 7% YoY but grew 10% sequentially as Dahej capacity issues are being addressed; 7-8 launches expected from Q1 FY25. Management views 31.8% EBITDA margin as the new sustainable base with further expansion levers from operating leverage in Brazil and U.S. The company targets 50-100bps annual margin improvement and 5-5.5% R&D spend next fiscal. Risk includes pending FDA inspection at Indrad and intensifying chronic segment competition in India.
Colored figures show movement against the previous available record.
Guidance to track
- Management explicitly stated current margin levels represent the new floor with operating leverage and price increases providing annual expansion. Target is 50-100bps improvement annually.
- New product launches will begin from Q1 next fiscal year to fuel growth. Management expects the U.S. business trajectory to move upward with improved scale.
- Increased R&D investment planned as U.S. launches commence and pipeline develops for future growth.
- New tenders won during Q3 will start delivering incremental sales from Q2 of next fiscal year, with management guiding upward revenue trend.
Risks flagged
- When explicitly asked about regulatory status of Indrad facility, management confirmed it is still pending inspection. This remains an unresolved regulatory risk for the U.S. supply chain.
- Multiple peers expanding into diabetes, cardiac, gastro, and CNS segments where Torrent is strong. Management acknowledged increased competition but relied on new launch track record and field force expansion as defense.
- Some high-volume products shifted from Indrad to CMO to address Dahej constraints. While management expects new launches from Q1 FY25, the capacity optimization is still in progress with execution risk.
- Other income includes INR 35 crore of Forex translation losses that management expects to reverse in coming quarters, introducing earnings volatility dependent on currency movements.
Key quotes
- Our operating EBITDA margins at 31.8% looks to be the new sustainable base going from here.
- We are referring to positive operating profits before R&D. We are kind of breakeven I would say, at this point. From here, we should start looking up.
- The focus has been to ensure that new product launch performance is the maximum possible. Our pipeline is robust, and our field force expansion, which has now been ongoing for the last 18-24 months, does give us enough headroom to continue the other market volume growth for the foreseeable coming quarters.
Research modules